CN Patent

CN120529900A — 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Assigned to Oryzon Genomics SA · Expires 2025-08-22 · 1y expired

What this patent protects

本发明涉及LSD1抑制剂(或其药学上可接受的盐)和Menin抑制剂(或其药学上可接受的盐)的组合。该组合特别用于治疗癌症，包括血液癌症，例如急性髓性白血病或骨髓增生异常综合征。

USPTO Abstract

本发明涉及LSD1抑制剂(或其药学上可接受的盐)和Menin抑制剂(或其药学上可接受的盐)的组合。该组合特别用于治疗癌症，包括血液癌症，例如急性髓性白血病或骨髓增生异常综合征。

Drugs covered by this patent

Patent Metadata

Patent number
CN120529900A
Jurisdiction
CN
Classification
—
Expires
2025-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Oryzon Genomics SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.